Health-economic benefits of anti-CD20 treatments in relapsing multiple sclerosis estimated using a treatment-sequence model.

Ide Smets,Matthijs Versteegh,Simone Huygens,Cato Corsten,Beatrijs Wokke,Joost Smolders

Multiple sclerosis journal - experimental, translational and clinical（2023）

引用 0|浏览6

暂无评分

摘要

Our model showed no clear difference in cost-effectiveness between ocrelizumab and ofatumumab. Hence, prescribing the least costly anti-CD20 mAb can democratise MS care without a loss in health benefits.

查看译文

关键词

multiple sclerosis,health-economic,treatment-sequence

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要